SCHEMBL6575204

SCHEMBL6575204

OCc1cc([C@H]2O[C@@H](n3cnc4c(Nc5ccccc5Cl)ncnc43)[C@H](O)[C@@H]2O)on1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.51
ALDH1A1 P00352 1/20 0.51
GLA P06280 1/20 0.51
PMP22 Q01453 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
NPC1 O15118 1/20 0.51
NPY1R P25929 1/20 0.51
HTT P42858 1/20 0.51
NPY2R P49146 1/20 0.51
RAB9A P51151 1/20 0.51
SLC29A1 Q99808 1/20 0.51
RXFP1 Q9HBX9 1/20 0.51
CYP1A2 P05177 1/20 0.51
TSHR P16473 1/20 0.51
NFKB1 P19838 1/20 0.51
MAPK1 P28482 1/20 0.51
CYP2C19 P33261 1/20 0.51
THPO P40225 1/20 0.51
ADORA3 P0DMS8 2/20 0.50
ADORA2A P29274 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6572976 0.92 ADORA3 (0.52) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6575302 0.92 ADORA3 (0.53) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6576699 0.90 ADORA3 (0.54) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6572847 0.88 ADORA3 (0.68) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6576895 0.86 ADORA3 (0.48) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6575152 0.85 ADORA3 (0.55) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6572733 0.82 ADORA3 (0.56) LMNAALDH1A1GLAPMP22SMN1; SMN2
SCHEMBL6574586 0.82 ADORA3 (0.52) ADORA3ADORA2AADORA2BADORA1
SCHEMBL6573937 0.81 ADORA3 (0.54) CYP1A2MAPK1ADORA3ADORA2AADORA2B
SCHEMBL6573910 0.81 ADORA1 (0.57) RXFP1CYP1A2MAPK1ADORA3ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1090019-B1 ADENOSINE DERIVATIVES GLAXO GROUP LTD (GB) 2004-09-29 EP claimed
JP-3378240-B2 2003-02-17 JP claimed
JP-2002518509-A 2002-06-25 JP claimed
EP-1090019-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 2001-04-11 EP claimed
WO-1999067262-A1 ADENOSINE DERIVATIVES GLAXO GROUP LIMITED (GB) 1999-12-29 WO claimed
EP-1090019-B1 ADENOSINE DERIVATIVES GLAXO GROUP LTD (GB) 2004-09-29 EP disclosed
EP-1447407-A1 Adenosine derivatives GLAXO GROUP LIMITED (GB) 2004-08-18 EP disclosed
US-6677316-B2 TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL SMITHKLINE BEECHAM CORPORATION 2004-01-13 US disclosed
US-20030096788-A1 Adenosine derivatives GLAXO WELLCOME INC. 2003-05-22 US disclosed
US-6492348-B1 Adenosine derivatives SMITHKLINE BEECHAM CORPORATION 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096788-A1 Adenosine derivatives ADORA3, ADORA2A, ADORA1 LMNA 1446/4885ALDH1A1 239/4885GLA 2469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.